VERDICT-MRI Analysis of False Positives in Prostate Mp-MRI
Snigdha Sen1, Vanya Valindria1, Hayley Pye2, Alistair Grey3, Aiman Haider4, Alex Freeman4, Caroline Moore3, Hayley Whitaker2, Shonit Punwani5, Saurabh Singh5, and Eleftheria Panagiotaki1
1Centre for Medical Image Computing, University College London, London, United Kingdom, 2Molecular Diagnostics and Therapeutics Group, University College London, London, United Kingdom, 3Department of Urology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, 4Department of Pathology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, 5Centre for Medical Imaging, University College London, London, United Kingdom
Mp-MRI has moderate specificity for the diagnosis of prostate cancer, resulting in many false positive results and unnecessary biopsies for patients with other prostatic diseases. This work presents an approach using VERDICT-MRI to investigate differences in microstructural parameter estimates between normal prostate tissue, false positive lesions and clinically-significant cancer. The VERDICT intracellular volume fraction and intrinsic diffusivity in the extracellular-extravascular space can discriminate false positive lesions with greater accuracy than the clinical ADC from mp-MRI. These results show VERDICT has the potential to identify false positives and reduce unnecessary biopsies in prostate patients.
This abstract and the presentation materials are available to members only;
a login is required.